hsa‑miR‑455‑3P as a predictive biomarker of anemia in patients with non‑small cell lung cancer treated with carboplatin plus paclitaxel

Vasconcelos,Pedro Eduardo Nascimento Silva; Seguin,Cecília Souto; Barbeiro,Aristóteles De Souza; Zambon,Lair; Honma,Helen Naemi; Perroud Jr,Maurício Wesley; Geraldo,Murilo Vieira; Pincinato,Eder De Carvalho; Moriel,Patricia

doi:10.3892/ol.2024.14350

hsa‑miR‑455‑3P as a predictive biomarker of anemia in patients with non‑small cell lung cancer treated with carboplatin plus paclitaxel

Authors:
- Pedro Eduardo Nascimento Silva Vasconcelos
- Cecília Souto Seguin
- Aristóteles De Souza Barbeiro
- Lair Zambon
- Helen Naemi Honma
- Maurício Wesley Perroud Jr
- Murilo Vieira Geraldo
- Eder De Carvalho Pincinato
- Patricia Moriel
View Affiliations

Affiliations: School of Medical Science, Universidade Estadual de Campinas, Campinas, São Paulo 13083-888, Brazil, School of Medical Science, Universidade Estadual de Campinas, Campinas, São Paulo 13083‑888, Brazil, Institute of Biology, Universidade Estadual de Campinas, Campinas, São Paulo 13083-970, Brazil, Faculty of Pharmaceutical Science, Universidade Estadual de Campinas, Campinas, São Paulo 13083-871, Brazil
Published online on: March 21, 2024 https://doi.org/10.3892/ol.2024.14350
Article Number: 219

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of cancer‑related morbidity and mortality worldwide. The initial treatment of lung cancer depends on the definition of the tumor type and its staging. The most common treatment is chemotherapy, and the first‑line treatment is a combination of carboplatin and paclitaxel. Although this treatment has good efficacy, there is a high prevalence of adverse events, particularly hematological reactions. Studies on new biomarkers related to these adverse events, such as circulating microRNAs (miRNAs/miRs), are important for optimizing the quality of life of patients. miRNAs have high stability in several biological fluids and they have specific expressions in different tissues or pathologies. Thus, the present study aimed to assess the relationship between circulating miRNAs and adverse hematologic reactions caused by treatment with carboplatin + paclitaxel in patients with lung cancer. Blood was collected from patients before and 15 days after chemotherapy for hematological adverse reaction analysis, microarray and quantitative (q)PCR validation. Adverse reactions were classified according to the Common Terminology Criteria for Adverse Events v4.0. Microarray analysis was performed using plasma from six patients without anemia and six patients with anemia, and nine miRNAs were differentially expressed. miR‑1273g‑3p, miR‑3613‑5p and miR‑455‑3p, identified using microarray, were assessed using qPCR in 20 patients without anemia and 26 patients with anemia. Bioinformatic analyses of miR‑455‑3p were performed using miRWalk, the Database for Annotation, Visualization and Integrated Discovery and GeneMania software. Microarray analysis of patients with and without anemia revealed nine significant differentially‑expressed plasma miRNAs among these patients. Of these, miR‑1273g‑3p, miR‑3613‑5p and miR‑455‑3p were chosen for further assessment. Only miR‑455‑3p demonstrated a significant reduction in expression (P=0.04) between the groups before chemotherapy with carboplatin + paclitaxel. Bioinformatics analysis of miR‑455‑3p revealed a relationship between this miRNA and the hematopoietic pathway, particularly with respect to the RUNX family transcription factor 1 (RUNX1) and TAL bHLH transcription factor 1, erythroid differentiation factor (TAL1) genes. The most prevalent adverse reactions in patients with lung cancer treated with carboplatin + paclitaxel were hematological, particularly anemia. This adverse reaction, caused by dysfunction of the hematopoietic system, may be explained by a possible association between the important genes in this system, RUNX1 and TAL1, and hsa‑miR‑455‑3p.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Duma N, Santana-Davila R and Molina JR: Non-Small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
3	Sateia HF, Choi Y, Stewart RW and Peairs KS: Screening for lung cancer. Semin.Oncol. 44:74–82. 2017. View Article : Google Scholar : PubMed/NCBI
4	Shroff GS, de Groot PM, Papadimitrakopoulou VA, Truong MT and Carter BW: Targeted therapy and immunotherapy in the treatment of non-small cell lung cancer. Radiol Clin North Am. 56:485–495. 2018. View Article : Google Scholar : PubMed/NCBI
5	López-Castro R, García-Peña T, Mielgo-Rubio X, Riudavets M, Teixidó C, Vilariño N, Couñago F and Mezquita L: Targeting molecular alterations in non-small-cell lung cancer: What's next? Per Med. 19:341–359. 2022. View Article : Google Scholar : PubMed/NCBI
6	Luo W, Wang Z, Tian P and Li W: Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: A meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol. 144:1851–1859. 2018. View Article : Google Scholar : PubMed/NCBI
7	Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, et al: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 29 (Suppl 4):iv192–iv237. 2018. View Article : Google Scholar : PubMed/NCBI
8	Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, et al: Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 19:1441–1464. 2021. View Article : Google Scholar : PubMed/NCBI
9	Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C and Pérez JM: Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 7:3–18. 2007. View Article : Google Scholar : PubMed/NCBI
10	Capriotti K, Capriotti JA, Lessin S, Wu S, Goldfarb S, Belum VR and Lacouture ME: The risk of nail changes with taxane chemotherapy: A systematic review of the literature and meta-analysis. Br J Dermatol. 173:842–845. 2015. View Article : Google Scholar : PubMed/NCBI
11	NIH National Heart, Lung and Blood Institute, . What is anemia? https://www.nhlbi.nih.gov/health/anemiaOctober 4–2023
12	Rodgers DM III, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, et al: Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 10:628–653. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T: Identification of novel genes coding for small expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
14	Lau NC, Lim LP, Weinstein EG and Bartel DP: An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 294:858–862. 2001. View Article : Google Scholar : PubMed/NCBI
15	Lee RC and Ambros V: An extensive class of small RNAs in Caenorhabditis elegans. Science. 294:862–864. 2001. View Article : Google Scholar : PubMed/NCBI
16	Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ and Wang K: The microRNA spectrum in 12 body fluids. Clin Chem. 56:1733–1741. 2010. View Article : Google Scholar : PubMed/NCBI
17	Pereira TC: Introduction to the world of microRNAs. Sociedade Brasileira de Genética; Ribeirão Preto, Brazil: pp. 442015, (In Portuguese).
18	Zhong S, Golpon H, Zardo P and Borlak J: miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl Res. 230:164–196. 2021. View Article : Google Scholar : PubMed/NCBI
19	Vasconcelos PE, Visacri MB, Pincinato EC, Torso NG, Seguin CS, Zambon L, Barbeiro AS, Junior MW and Moriel P: miRNAs as biomarkers of adverse drug reactions to platinum-based agents in patients with non-small-cell lung cancer. Biomark Med. 15:1067–1069. 2021. View Article : Google Scholar : PubMed/NCBI
20	Karnofsky DA and Burchenal JH: The clinical evaluation of chemotherapeutic agents. MacLeod CM: Evaluation of chemotherapeutic agents. Columbia University Press; New York, USA: pp. 1961946
21	U.S Department of Health and Human Services, . Common Terminology Criteria for Adverse Events (CTCAE). U.S Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Version 4.0. 2010, https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29.xlsMarch 11–2024
22	Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T and Hatzigeorgiou AG: DIANA-miRPath v3. 0: deciphering microRNA function with experimental support. Nucleic Acids Res. 43:W460–W466. 2015. View Article : Google Scholar : PubMed/NCBI
23	Rotor-Gene Q 2.3.5-Windows platforms. https://www.qiagen.com/us/resources/resourcedetail?id=9d8bda8e-1fd7-4519-a1ff-b60bba526b57&lang=enJanuary 30–2024
24	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
25	Dweep H and Gretz N: MiRWalk2.0: A comprehensive atlas of microRNA-target interactions. Nat Methods. 12:6972015. View Article : Google Scholar : PubMed/NCBI
26	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
27	Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al: The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 38:W214–W220. 2010. View Article : Google Scholar : PubMed/NCBI
28	Zhao Y, Yan M, Yun Y, Zhang J, Zhang R, Li Y, Wu X, Liu Q, Miao W and Jiang H: MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer. Oncol Rep. 37:2449–2458. 2017. View Article : Google Scholar : PubMed/NCBI
29	Yang H, Wei YN, Zhou J, Hao TT and Liu XL: MiR-455-3p acts as a prognostic marker and inhibits the proliferation and invasion of esophageal squamous cell carcinoma by targeting FAM83F. Eur Rev Med Pharmacol Sci. 21:3200–3206. 2017.PubMed/NCBI
30	Gao X, Zhao H, Diao C, Wang X, Xie Y, Liu Y, Han J and Zhang M: miR-455-3p serves as prognostic factor and regulates the proliferation and migration of non-small cell lung cancer through targeting HOXB5. Biochem Biophys Res Commun. 495:1074–1080. 2018. View Article : Google Scholar : PubMed/NCBI
31	Guo J, Liu C, Wang W, Liu Y, He H, Chen C, Xiang R and Luo Y: Identification of serum miR-1915-3p and miR-455-3p as biomarkers for breast cancer. PLoS One. 13:e02007162018. View Article : Google Scholar : PubMed/NCBI
32	Yi X, Wang Y and Xu S: MiR-455-3p downregulation facilitates cell proliferation and invasion and predicts poor prognosis of osteosarcoma. J Orthop Surg Res. 15:4542020. View Article : Google Scholar : PubMed/NCBI
33	Lam K and Zhang DE: RUNX1 and RUNX1-ETO: Roles in hematopoiesis and leukemogenesis. Front Biosci (Landmark Ed). 17:1120–1139. 2012. View Article : Google Scholar : PubMed/NCBI
34	Okuda T, Nishimura M, Nakao M and Fujita Y: RUNX1/AML1: A central player in hematopoiesis. Int J Hematol. 74:252–257. 2001. View Article : Google Scholar : PubMed/NCBI
35	Ichikawa M, Yoshimi A, Nakagawa M, Nishimoto N, Watanabe-Okochi N and Kurokawa M: A role for RUNX1 in hematopoiesis and myeloid leukemia. Int J Hematol. 97:726–734. 2013. View Article : Google Scholar : PubMed/NCBI
36	Lécuyer E and Hoang T: SCL: From the origin of hematopoiesis to stem cells and leukemia. Exp Hematol. 32:11–24. 2004. View Article : Google Scholar : PubMed/NCBI
37	Vagapova ER, Spirin PV, Lebedev TD and Prassolov VS: The Role of TAL1 in hematopoiesis and leukemogenesis. Acta Naturae. 10:15–23. 2018. View Article : Google Scholar : PubMed/NCBI
38	Reynaud D, Ravet E, Titeux M, Mazurier F, Rénia L, Dubart-Kupperschmitt A, Roméo PH and Pflumio F: SCL/TAL1 expression level regulates human hematopoietic stem cell self-renewal and engraftment. Blood. 106:2318–2328. 2005. View Article : Google Scholar : PubMed/NCBI